Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton.
Conventional anticancer agents may display antiangiogenic effects, but the underlying mechanism is poorly understood. We determined the antiangiogenic properties of cisplatin, doxorubicin, and the microtubule-targeting agents docetaxel, epothilone B, and vinblastine at concentrations not affecting cell proliferation. We also assessed tubulin and actin morphology and the activity of two key molecules in cell motility, the small Rho GTPases Cdc42 and Rac1. The highest non-toxic concentration (HNTC) of each drug was defined as the concentration inhibiting a maximum of 10% human umbilical vein endothelial cell growth on a 1-hour drug exposure, being for cisplatin 10 micromol/L, doxorubicin 100 nmol/L, docetaxel 10 nmol/L, epothilone B 1 nmol/L, and vinblastine 10 nmol/L. Comparative endothelial cell functional assays using HNTCs for an exposure time of 1 hour indicated that endothelial cell migration in the wound assay, endothelial cell invasion in a transwell invasion system, and endothelial cell formation into tubelike structures on a layer of Matrigel were significantly inhibited by docetaxel, epothilone B, and vinblastine (P < 0.05), but not by cisplatin and doxorubicin. Docetaxel was slightly more efficient in the inhibition of endothelial cell motility than epothilone B and vinblastine. Fluorescence microscopy revealed that only the microtubule-targeting agents affected the integrity of the tubulin and F-actin cytoskeleton, which showed disturbed microtubule structures, less F-actin stress fiber formation, and appearance of nuclear F-actin rings. These observations were associated with early inhibition of Rac1 and Cdc42 activity. In conclusion, HNTCs of microtubule-targeting agents efficiently reduce endothelial cell motility by interference with microtubule dynamics preventing the activation of Rac1/Cdc42 and disorganizing the actin cytoskeleton.
Bijman
Marcel N A
MN
Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
van Nieuw Amerongen
Geerten P
GP
Laurens
Nancy
N
van Hinsbergh
Victor W M
VW
Boven
Epie
E
D008841:Actin Cytoskeleton / Q000378:metabolism / Q000502:physiology; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D002945:Cisplatin / Q000494:pharmacology; D003599:Cytoskeleton / Q000187:drug effects* / Q000378:metabolism; D004317:Doxorubicin / Q000276:immunology; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D034261:Epothilones / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008870:Microtubules / Q000187:drug effects*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D011554:Pseudopodia / Q000378:metabolism / Q000502:physiology; D022502:Stress Fibers / Q000378:metabolism / Q000502:physiology; D050257:Tubulin Modulators / Q000494:pharmacology*; D014747:Vinblastine / Q000494:pharmacology; D020764:cdc42 GTP-Binding Protein / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D020830:rac1 GTP-Binding Protein / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D034261:Epothilones; D050257:Tubulin Modulators; D014747:Vinblastine; D004317:Doxorubicin; D020764:cdc42 GTP-Binding Protein; D020830:rac1 GTP-Binding Protein; D002945:Cisplatin; C093788:epothilone B